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Abstract
Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even
with the newer biological therapies available today.
Case presentations: We present two patients with severe chronic plaque psoriasis who received
numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial
treatment with efalizumab (anti-CD11a), but then experienced a flare of their disease after missing
a dose. However, after disease stablization, both patients responded well to re-introduction of
efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-α).
Conclusion: These cases are presented to characterize this "flare" reaction, and to inform health
care providers that efalizumab can still be administered after disease flare, and again may be a
successful therapy.
Background
Psoriasis may be a long-lasting disease resulting in great
morbidity in affected patients. Newer biological therapies
may offer a real alternative to those with severe disease,
and they are associated with a different toxicity profile
than traditional systemic therapies [1]. The agents cur-
rently approved by the US FDA are alefacept (anti-CD2,
Amevive, Biogen), efalizumab (anti-CD11a, Raptiva,
Genentec Inc) and etanercept (anti-TNF receptor, Enbrel,
Amgen). Infliximab (anti-TNF-α, Remicade, Centocor)
has not yet been approved for psoriasis vulgaris, although
it has recently been approved for psoriatic arthritis.
Efalizumab is a humanized monoclonal antibody target-
ing the α chain of the T cell adhesion integrin lymphocyte
function-associated antigen (LFA)-1. The LFA-1- intracel-
lular adhesion molecule (ICAM)-1 interaction plays a cru-
cial role in T cell adhesion at several key points in immune
activation pathways. By binding to ICAM-1 on dendritic
cell (DCs), endothelial cells and keratinocytes, T cells may
be activated, migrate, and interact with keratinocytes
respectively. The mechanism of action is not yet com-
pletely understood, however during therapy peripheral
lymphocytosis is observed, which is most likely due to
inhibition of T cell trafficking and blockade of memory T
cells entering inflamed skin [2]. Efalizumab is associated
with a rebound flare reaction in approximately 5% of
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patients when therapy is ceased [3]. However, we were not
able to find reports of exacerbations of psoriasis while on
therapy, as in these cases.
Infliximab is a chimeric anti-TNF-α monoclonal antibody
which gives excellent results in the majority of patients at
a dose of 5 mg/kg per infusion [4]. Case reports of combi-
nation therapies with two biological agents have not yet
been reported for psoriasis. The main concern with this
therapeutic strategy is the risk of opportunistic infection
and malignancy, which should be constantly considered.
We present these cases to document the clinical and histo-
logical appearance of the flare reaction occurring during
previously-effective efalizumab therapy, and demonstrate
that this agent can be reintroduced with good clinical
effect.
Case presentations
Patient 1 is a 51 year old man from Ecuador, with severe
large plaque psoriasis for 15 years, and a strong family his-
tory of psoriasis. His medical background included recent-
onset hypertension and diabetes, and renal calculi. He
takes lisinopril and glyburide, as well as doxepin and
atarax when required. His past psoriasis treatments
include topical steroids, methotrexate (not tolerated due
to nausea), and UVB with minimal effect.
He was first seen at The Rockefeller University, NY, USA,
in December 2000 and received numerous courses of bio-
logical therapies in the context of our clinical trials pro-
gram. He initially received efalizumab (100 mg [1 mg/kg]
sc weekly for 12 weeks) with good effect. His re-treatment
with efalizumab was required in May 2001 because of a
sunburn-induced flare, and was permitted under our clin-
ical trial protocol. Another psoaisis flare in Sept 2001 was
treated with alefacept (7.5 mg IV for 12 weekly doses)
with good effect. Subsequent disease exacerbations were
managed well with a course of daclizumab (anti-CD25)
therapy, NB-UVB, and cyclosporine.
Due to previous success with efalizumab and recent USA
FDA approval, a disease flare in March 2004 was managed
with efalizumab at the standard dose (1 mg/kg/wk sc) at
a private clinic. However, he missed a dose in June 2004
and his skin flared again, so he re-attended our clinic (Fig
1). Despite missing a dose, there was still leukocyte
CD11a saturation by efalizumab (Fig. 2B, solid line iden-
tical to isotype, shaded). At this time, his psoriasis was
complicated by Staphlococcal skin infection. To gain con-
trol of his skin disease and while waiting for his skin infec-
tion to respond to antibiotic treatment (dicloxicillin), he
was given low-dose NB-UVB. Efalizumab was re-com-
menced in September 2004 with good result (110 mg/wk,
1 mg/kg). This has been continued and the patient is cur-
rently in remission.
Immunohistochemistry during the flare reaction (Fig. 3),
shows there are relatively less lesional CD3+ cells com-
pared to untreated psoriasis, and they are predominantly
all CD8+. CD103 is also expressed on epidermal T cells. In
addition, there are abundant CD11c+ and inducible nitric
oxide synthase (iNOS)+ inflammatory cells infiltrating the
dermis and epidermis. CD14+ cells are relatively rare (not
shown).
Patient 2 is a 33 year-old Australian-born Caucasian
female with a 14 year history of severe plaque psoriasis,
and psoriatic arthritis for 12 years. Her first presentation
of psoriasis was with erythroderma at 19 years old. Her
past medical history included appendicectomy, infectious
mononucleosis, and Chloroquine-resistant P. falciparum
malaria at age 15 years following travel to Papua New
Guinea. She was not taking any medications at the time of
initial referral to Royal Prince Alfred Hospital Department
of Dermatology, New South Wales, Australia, in 1994.
Past rotational treatments for her psoriasis and psoriatic
arthritis included cyclosporine (1990 and 1995), meth-
otrexate (1993 and 1996), acitretin (1994 and 1997), as
well as periodic courses of NB-UVB. She was hospitalized
in 1999 for erythrodermic psoriasis. In 2001 her psoriasis
flared and other therapies tried without success were myc-
ophenolate mofetil, hydroxyurea, tacrolimus, and thio-
guanine. From July 2001 to November 2002 she received
periodic treatment with cyclosporine and acitretin ther-
apy, with poor disease control.
Over the next 2.5 years, this patient was treated with a
number of newer biological therapies with standard dos-
ing, sometimes requiring cyclosporine cover and subse-
quent withdrawal as the patient responded. Etanercept
(anti-TNF receptor) (Dec 2002–Feb 2003, 25 mg sc twice
week) was initially successful, but was ceased on relapse to
erythroderma. Alefacept (anti-CD2) (15 mg IM weekly for
3 months) had no beneficial effect.
Efalizumab (anti-CD11a) (80 mg [1 mg/kg] sc weekly,
Dec 2003) induced a dramatic clinical response, and after
6 weeks, cyclosporine was ceased. The patient missed the
18th dose of efalizumab, but the regular dose was given at
the subsequent visit. Two days after the "catchup" dose,
the patient developed a psoriatic flare involving extensive
plaques on all body surfaces. Immunohistochemistry at
this time (Fig. 3) shows similar results to patient 1: there
are relatively reduced CD3+ and CD8+ cells, epidermal T
cells are CD103+, and there are abundant CD11c+ and
iNOS+  inflammatory cells infiltrating the dermis and
epidermis.
During this flare, NB-UVB was administered concomi-
tantly with efalizumab, however a UVB-induced burn wasBMC Dermatology 2005, 5:9 http://www.biomedcentral.com/1471-5945/5/9
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associated with recurrence of her psoriasis. However, by
June 2004 there was almost confluent severe plaque pso-
riasis again with features of erythroderma. The efalizumab
dose was increased to 125 mg (1.5 mg/kg) sc weekly, but
was ceased in Sept 2004 as there was no further
improvement.
Clinical photos of patient 1 during the flare reaction in June 2004 (upper panels), with follow-up photos after standard-dose  treatment with efalizumab for three months (lower panels) Figure 1
Clinical photos of patient 1 during the flare reaction in June 2004 (upper panels), with follow-up photos after standard-dose 
treatment with efalizumab for three months (lower panels).BMC Dermatology 2005, 5:9 http://www.biomedcentral.com/1471-5945/5/9
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Infliximab (anti-TNF-α) (400 mg [5 mg/kg] at 0 and 2
weeks, followed by 400 mg every 6 weeks) was com-
menced with excellent effect for 4 months, when the
patient then experienced another flare of her psoriasis. It
was decided to carefully combine infliximab and efalizu-
mab therapy. In February 2005, 62.5 mg (0.7 mg/kg)
efalizumab was given sc, and a second dose of 125 mg
(1.4 mg/kg) a week later, and she started to respond clin-
ically. She is currently well controlled on this therapy.
Discussion
We present two cases of severe large plaque psoriasis, with
both patients clearing with initial efalizumab treatment,
experiencing a flare of their disease after missing a dose of
therapy, and responding well to reintroduction of efalizu-
mab after disease stablization. These case reports illustrate
that this therapy can be safely reintroduced with good
clinical effect in those with limited therapeutic options
(Fig. 1), and support our view that this flare reaction is not
an allergic hypersensitivity event.
During the flare reaction, flow cytometric analysis of cir-
culating lymphocytes demonstrated that there was persist-
ing saturation of the efalizumab-CD11a epitope, and
there was also down-regulation of CD11a expression (Fig.
2). The possible mechanisms of psoriasis flare while on a
saturating dose of efalizumab include (1) allergic hyper-
sensitivity, (2) the development of anti-human neutraliz-
ing antibodies, (3) lowering of tissue concentration of the
drug, or (4) an external trigger inducing other types of leu-
kocytes to enter the skin via an LFA-1-independent mech-
anism causing inflammation. Safe and effective
reintroduction of efalizumab, and the lack of eosinophils
on biopsy argue for a non-hypersensitivity mechanism of
the flare. If neutralizing antibodies had developed, there
would not be efalizumab-CD11a epitope saturation, and
further administration would not lead to skin clearing. It
is difficult to correlate circulating levels and tissue levels of
efalizumab, but it is possible that missing a dose might
decrease tissue levels. Finally, we cannot rule out the pos-
sibility that entry of non-lymphocyte leukocytes into the
skin due to an external trigger such as skin infection might
lead to skin inflammation, especially in patient 1. How-
ever, the frequency of flare reactions is much less than
external events, suggesting that it is an uncommon
consequence.
We have also characterized this flare reaction histologi-
cally (Fig. 3), demonstrating two main points. In these
cases, we found increased CD8+ dominant T cell infil-
trates. However, overall there were fewer T cells compared
to other psoriasis patients before efalizumab treatment.
The CD8+ T cells are located mostly in the epidermis and
they express the integrin αE (CD103). The αE subunit com-
bines with the β7 subunit and binds to E-cadherin on
keratinocytes, which mediates epidermal T cell trafficking.
Thus CD8+ T cell trafficking during LFA-1 (a β2 integrin)
blockade by efalizumab may be regulated by αEβ7
integrin, permitting epidermal entry of T cells during dis-
ease flare.
Secondly, there are abundant CD11c+ and iNOS+ cells in
the dermis and epidermis during flare reactions. These
markers represent a dendritic cell subset, and may be
important in the pathogenesis of psoriasis. These cells
may be able to enter the skin via an LFA-1 independent
mechanism, and may be playing a direct role in the induc-
tion of or maintenance of psoriasis, causing the pheno-
typic features of erythema and hyperplasia.
Although we would always prefer the use of a single ther-
apeutic agent where possible, the concurrent use of two
biologicals of different classes can be considered in those
patients with difficult-to-treat severe psoriasis vulgaris
with limited therapeutic options. The main reason for
caution with combination therapy is that the safety of
such combinations is not yet established and so there is
limited safety data. One of the main potential risks of such
a combination is a decreased response to infection.
Patients should be educated about this risk and seek
FACS analysis of peripheral blood lymphocytes (gated) of  patient 1, pre-treatment (A) and during flare (B) Figure 2
FACS analysis of peripheral blood lymphocytes (gated) of 
patient 1, pre-treatment (A) and during flare (B). Isotype 
(Becton Dickenson) is shaded, solid line shows T cell binding 
of efalizumab-FITC (custom design, Genetech), and dotted 
line shows binding of an anti-CD11a antibody which binds to 
a different epitope (clone 25.3, Immunotech). The pre-treat-
ment sample (A) shows high-level binding of both anti-
CD11a antibodies. The sample acquired during flare (B) 
shows the ex-vivo level of binding of efalizumab-FITC is the 
same as isotype, as there is already saturation of this CD11a 
epitope by therapeutic administration of efalizumab. There is 
also reduced binding of the 25.3 epitope indicating significant 
down-regulation of CD11a surface expression.BMC Dermatology 2005, 5:9 http://www.biomedcentral.com/1471-5945/5/9
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Immunohistochemistry of lesional skin biopsies during psoriatic flare of patient 1 and 2, showing similar features (magnification  × 10) Figure 3
Immunohistochemistry of lesional skin biopsies during psoriatic flare of patient 1 and 2, showing similar features (magnification 
× 10). Haematoxylin and eosin (H&E) stain showing epidermal hyperplasia, elongation of rete ridges, dilatation of dermal papilla 
blood vessels, and mononuclear and neutrophil leukocyte infiltration. Some CD3 (BD) T cells infiltrate the dermis and epider-
mis, and these are mostly CD8+ (BD Pharmingen), although there are less T cells than during untreated psoriasis. Most of the 
epidermal T cells are CD103+ (Biodesign, Kennebunnk, ME). CD11c+ (BD Pharmingen) and iNOS+ (R&D Systems) cells are 
dramatically increased compared to non-lesional skin, and stain in a dendritic pattern.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Dermatology 2005, 5:9 http://www.biomedcentral.com/1471-5945/5/9
Page 6 of 6
(page number not for citation purposes)
medical attention early if they develop any new symptoms
of infection. The main long-term risk of any of the biolog-
icals includes malignancy, and this may be increased
when more than one agent is used concurrently. Again,
careful regular examination and screening where appro-
priate is warranted. The length of time a person is on two
agents should be tailored to the patient.
Conclusion
In conclusion, we present two patients who experienced a
flare of their severe psoriasis while on initially effective
efalizumab therapy. Patient 1 still had saturation of avail-
able efalizumab-CD11a sites on circulating lymphocytes,
even though he had missed a dose, and was presumably
in a therapeutic range. Subsequently, both patients were
able to restart efalizumab with effect, one requiring con-
current administration with infliximab. This is reassuring,
given the limited therapeutic options for certain psoriasis
patients. We have also characterized the histological
appearance of this flare reaction, with abundant CD11c+
and iNOS+ DCs, and less CD3, CD8+ and CD103+ cells
than are normally seen in psoriasis. These DCs may be
playing a critical role in the psoriasis flare and possibly
psoriasis.
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